Abstracts patterns, costs, life expectancy, and discount rates. Patients with both an infection and at least one acute organ dysfunction diagnosis (ICD-10) recorded were selected from Huddinge university hospital in Sweden (n = 55). Direct costs for drugs, intensive care, and general wards up to 28 days, and to final discharge were determined according to the hospital resource and cost assignment system (2002 prices) . The cost of DAA was based on the average use in the trial and the Swedish price 2002.
RESULTS:
The cost-effectiveness ratio of an adjunct drotrecogin alfa (activated) compared with standard therapy alone in the base case including patients with failure in at least two organs was €19,500 per QALY based on Swedish data. The corresponding figure was €13,700 when results were transferred by the exchange rate. Higher ICU costs in Sweden compared to UK account for 45% of the difference whereas higher life expectancy among the UK patients account for 55%. CONCLUSIONS: Drotrecogin alfa (activated) is costeffective when compared to other accepted Health care interventions in Sweden. Local data application is important but does in this case not change the overall conclusion. 
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